welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
-
Matthew Kalady, MDMatthew Kalady, MD, holds the Krause-Lie...
-
Susan K. Peterson, PhD, MPHDr. Susan K. Peterson is a member at The...
-
Dealing with Ostomy LeaksNothing can be more upsetting to an osto...
-
Endoscopic Management of Familial Adenomatous Polyposis in Patients Refusing ColectomyBACKGROUND AND STUDY AIMS: Colectomy pr...
-
Chemoprevention of Colorectal CancerColorectal cancer has become one of the ...
-
Non Steroidal Anti-Inflammatory Drugs (NSAID) and Aspirin for Preventing Colorectal Adenomas and CarcinomasBACKGROUND : There is evidence from expe...
-
Andrew T. Chan, MD, MPHAndrew T. Chan is a Program Director, Ga...